William J. Peters Sells 7,426 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) CFO William J. Peters sold 7,426 shares of the company's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Amphastar Pharmaceuticals Trading Up 4.8 %

NASDAQ:AMPH traded up $2.22 during trading hours on Friday, reaching $48.31. The company's stock had a trading volume of 626,882 shares, compared to its average volume of 397,490. The firm has a 50-day simple moving average of $48.45 and a 200-day simple moving average of $44.13. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of 14.73, a PEG ratio of 0.97 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

AMPH has been the topic of a number of research analyst reports. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $63.00.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently bought and sold shares of AMPH. GAMMA Investing LLC grew its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC purchased a new stake in Amphastar Pharmaceuticals during the 2nd quarter valued at $55,000. Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after acquiring an additional 309 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after acquiring an additional 301 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.